Portfolio News
SHANGHAI, CHINA and BOSTON, MA,USA_-November 7, 2025—Argo Biopharmaceutical Co., Ltd. (Argo Biopharma), a clinical-stage small interfering RNA (siRNA) therapeutics company, today announced it will present Phase I data for BW-20805 at the American College of Allergy, Asthma & Immunology (ACAAI) 2025 Annual Scientific Meeting , taking place November 6–10 in Orlando, Florida, USA.
BW-20805 is an investigational siRNA therapy that targets and inhibits prekallikrein (PKK), a well-validated target for hereditary angioedema (HAE) treatment, offering the possibility of prevention of HAE attacks with a significant, long-term effect.
The poster presentation (POSTER ID: R094) , titled “Hereditary Angioedema Prophylaxis With Prekallikrein siRNA-Phase 1 Safety Outcomes And Prekallikrein Levels ”, will be presented throughout the ACAAI meeting. These data highlight that BW-20805 was well tolerated and demonstrated a favorable safety profile and achieved rapid, profound, and sustained reductions in plasma PKK levels.
Key findings :
- BW-20805 was generally well tolerated across all dose levels (50–600 mg), with no dose-dependent increase in treatment-emergent adverse events (TEAEs).
- No deaths, serious adverse events (SAEs) related to study drug, or discontinuations due to TEAEs were reported.
- Treatment with BW-20805 led to rapid, profound, and durable reductions in plasma PKK levels, achieving mean maximum reductions of approximately 75% (50 mg), 87% (150 mg),94% (300 mg), and 95% (600 mg).
- PKK suppression was sustained for up to 24 weeks, supporting the potential for 6-month dosing intervals.
- Other pharmacodynamic biomarkers, including plasma proenzyme activation and cleaved high-molecular-weight kininogen (cHMWK), also showed significant reductions, reinforcing the drug’s biological activity.
“We are pleased with the results shared at ACAAI, showing that BW-20805 was well tolerated across all dose levels, with rapid, profound, and durable reductions in plasma PKK levels achieved,” said Dr. Dongxu Shu, co-founder and Chief Executive Officer of Argo Biopharma. “We look forward to further advancing BW-20805 as a potential long-acting and effective therapy for people living with HAE.”
